ResMed
362 hedge funds and large institutions have $6.84B invested in ResMed in 2017 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 136 increasing their positions, 121 reducing their positions, and 35 closing their positions.
364% more call options, than puts
Call options by funds: $27.2M | Put options by funds: $5.85M
74% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 35
12% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 121
7% more funds holding
Funds holding: 339 → 362 (+23)
1.26% more ownership
Funds ownership: 61.23% → 62.49% (+1.3%)
1% more capital invested
Capital invested by funds: $6.76B → $6.84B (+$82.5M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$170M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$129M |
| 3 |
State Street
Boston,
Massachusetts
|
+$92.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$41.4M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$40.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$239M |
| 2 |
Bank of New York Mellon
New York
|
-$39.4M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$31.8M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$30.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$26.9M |
RMD Hedge Fund Activity: Q3 2017 in Review
362 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2017, worth a combined $6.84B — up 1.2% from $6.76B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new RMD positions and 35 closed out — a net gain of 26 holders — while 136 added to existing stakes and 121 trimmed.
The largest buyer was Vanguard Group, adding an estimated $170M. The largest seller was BlackRock, cutting an estimated $239M.
- 362 institutional investors held ResMed (RMD) as of Q3 2017, up from 339 in Q2 2017.
- Funds reported $6.84B of ResMed stock for Q3 2017, up 1.2% quarter-over-quarter.
- 61 funds opened new ResMed positions in Q3 2017 and 35 closed out, a net change of +26 holders.
- The largest ResMed buyer in Q3 2017 was Vanguard Group, an estimated $170M added.
- The largest ResMed seller in Q3 2017 was BlackRock, an estimated $239M sold.
Based on aggregated 13F filings for Q3 2017.